408538-29-4

Basic information

• Product Name: 3-amino-5-chloropicolinonitrile
• Synonyms: 3-amino-5-chloropicolinonitrile
• CAS NO: 408538-29-4
• Molecular Formula: C₆H₄ClN₃
• Molecular Weight: 153.56906
• Mol File: 408538-29-4.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-amino-5-chloropicolinonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-amino-5-chloropicolinonitrile(408538-29-4)
• EPA Substance Registry System: 3-amino-5-chloropicolinonitrile(408538-29-4)

Safety Data

• Hazardous Substances Data: 408538-29-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-amino-5-chloropicolinonitrile is used as a key intermediate in the synthesis of heterocyclic and bioactive molecules for pharmaceutical applications. Its unique structure and reactivity contribute to the development of new drugs with potential therapeutic benefits.
Used in Chemical Industry:
In the chemical industry, 3-amino-5-chloropicolinonitrile serves as an important building block for the production of various organic compounds. Its properties and structure enable the creation of new materials and compounds with diverse applications in different sectors.
Overall, 3-amino-5-chloropicolinonitrile is a versatile and valuable compound in both the pharmaceutical and chemical industries, playing a crucial role in the synthesis and development of innovative products.

Upstream product

• 90902-83-3 3-amino-2-bromo-5-chloropyridine 
• 75806-86-9 2-bromo-5-chloro-3-nitropyridine 
• 21427-61-2 5-chloro-3-nitropyridin-2-ol 
• 181123-11-5 5-chloro-2-cyano-3-nitropyridine 

Downstream Products

• 27330-34-3 3-amino-5-chloropicolinamide 
• 917757-12-1 4,7-dichloro-pyrido[3,2-d]pyrimidine 

Relevant articles and documents

IDENTIFICATION AND USE OF ERK5 INHIBITORS

The present invention covers heterocyclic compounds of general formula (I) in which T, U, Y, Z, R1 and R3 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer disorders, as a sole agent or in combination with other active ingredients.

FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREAMENT OF INFLAMMATION

Compounds are provided that act as potent antagonists of the CCR2 receptor. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2- mediated diseases and as controls in assays for the identification of CCR2 antagonists. A compound of the formula (I) or a salt thereof: where: R1 and R2 are each independently hydrogen, halogen, C1-8alkyl, -CN. or C1-8 haloalkyl, provided that at least one of R11or R2 is other than hydrogen; each R3 is independently hydrogen; R4 is hydrogen; R5 is halogen or C1-8 alkyl; R6 is hydrogen; X1 is CR7, N or NO; X2 and X4 are N or NO; X3 is CR7; X6 and X7 are each independently selected from CR7, N, and NO; each R7 is independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C2-8 alkyl, substituted or unsubstituted C2-8 alkeπyl, substituted or unsubstituted C2-8 alkynyl, -CN. =O, -NO2, -OR6, -OC(O)R8, -CO2R8, -C(O)R8, -C(O)NR0R8, -OC(O)NR9R8, -NR10C(O)R8, -NR10C(O)NR9R8, -NR9R8, -NR10CO2R8, -SR8, -S(O)R8, -S(O)2R8, -S(O)2NR9R8, -NR10S(O)2R8, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl and substituted or unsubstituted 3- to 10-membered heterocyclyl;

HETEROARYL SULFONAMIDES AND CCR2

Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.